Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Market Anticipated to Grow Globally at a CAGR of 23.6% during 2021-26

Published

on

Dublin, Oct. 11, 2021 (GLOBE NEWSWIRE) — The “Global Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Market Research Report: Forecast (2021-2026)” report has been added to ResearchAndMarkets.com’s offering.

The “Global Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Market” is likely to grow at a CAGR of around 23.6% during the forecast period, i.e., 2021-26, says the author. The market growth primarily attributes to the rising demand for reducing the cost of novel drug discovery and their production. Additionally, the adoption of artificial intelligence is significantly increasing, as faster, efficient, and cost-effective drug discovery is gaining momentum amongst the pharmaceutical industry stakeholders.

The research report, states that the burgeoning volume of data generated by the molecule screening processes & preclinical studies is another crucial factor fueling the adoption of artificial intelligence, thereby propelling market growth.

Global Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Market Have positively impacted by COVID-19 Pandemic

With the global Covid-19 pandemic outbreak in early 2020, the pharma and biotech companies have increasingly turned to artificial intelligence to enhance precision and speed in drug development. The pandemic has set the stage for massive investments toward fast development and trials of drugs.

Moreover, the adoption of artificial intelligence helps in offering a high level of precision to the complicated and time-consuming discovery phase in the drug development process, thereby leading to faster development of drugs and lower failure risk.

Companies Mentioned

  • Accutar Biotechnology
  • Ardigen
  • Atomwise Inc.
  • AiCure LLC
  • Berg LLc
  • Cloud Pharmaceuticals
  • Biovista
  • Cyclica Inc.
  • Symphony Innovations
  • GNS Healthcare

Market Segmentation

Oncology Dominated the Global Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Market with largest share

Based on the Therapeutic Application, the market bifurcates into Oncology, Cardiovascular Disease, Nervous System Disease, Respiratory Disorder, Metabolic Disorder, Immunologic Disease, and Infectious Disease. Of these segments, Oncology acquired the largest share of the Global Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Market in the previous few years.

AI helps in the early detection of cancer. Personalized medicine is necessary for the treatment of cancer as cancer treatments may vary for every patient. Thus, AI identifies genetic mutations, which further help oncologists design effective personalized medicine for cancer patients. Hence, these aspects aid the overall market growth cites the authors in their research report “Global Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Market Analysis, 2021”.

Contract Research Organization (CROs) to Dominate the Global Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Market During the Forecast Period.

Based on the End-User, the market segments into Biopharmaceutical Industry, Contract Research Organization (CROs), and Academic Institutes & Research Centers. For improving drug discovery and clinical trials, the end-users such as biopharmaceutical companies, contract research organizations, and academic institutions are assimilating AI-enabled solutions. However, Contract Research Organization (CROs) is likely to capture a significant share of the Global Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Market during the forecast period.

The segment growth owes to the increasing demand for maintaining the facility workflow and rearranging the work for enhancing the quality of work. AI-enabled solutions in the CROs are gaining popularity, thereby catalyzing the overall demand for drug discovery and clinical trials.

Regional Landscape

North America Attained the Largest Market Share

The region’s growth attributes to the high patient acceptance for advanced technologies and growing positive perception of AI amongst businesses. It further propels by the presence of the substantially large and well-established healthcare industry. Additionally, rising awareness regarding the benefits of integrating AI in the drug discovery process contributes to the Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Market growth in the region.

Market Drivers

Mounting Technological Advancement to Propel the Market Growth

Burgeoning technological advancements like AI, 4K Imaging, and IoT (Internet of Things) have resulted in surging the demand for integrating these high-end technologies in the healthcare industry. AI helps provide patient-centric treatment, better diagnostic services, and accurate decision-making, thereby recognizing errors in the current situations and providing better alternatives in complex scenarios. Hence, AI technology is likely to encourage the growth of the Drug Discovery and Clinical Trials Market.

Market Challenges

Lack of Skilled Personnel to Hamper the Market Growth

One of the most prominent challenges in the drug discovery phase is patient health. Dynamic activities interpret information about the documented effects of drugs and anticipate their side effects, which might be a major market restraint. Besides, lack of skilled staff and inadequate datasets for drug discovery & developments are other crucial factors likely to impact the market growth.

Key Topics Covered:

1. Start-up Ecosystem

2. Impact of COVID-19 on Global Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Market

3. Expert Verbatim – Interview Excerpts of 10 industry experts

4. Global Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Market Outlook, 2016-2026F

5. North America Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Market Outlook, 2016-2026F
5.1. Market Size & Analysis
5.2. Market Share & Analysis
5.3. The US Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Market Outlook, 2016-2026F
5.4. Canada Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Market Outlook, 2016-2026F
5.5. Mexico Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Market Outlook, 2016-2026F

6. South America Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Market Outlook, 2016-2026F
6.1. Market Size & Analysis
6.2. Market Share & Analysis
6.3. Brazil Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Market Outlook, 2016-2026F
6.4. Argentina Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Market Outlook, 2016-2026F

7. Europe Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Market Outlook, 2016-2026F
7.1. Market Size & Analysis
7.2. Market Share & Analysis
7.3. UK Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Market Outlook, 2016-2026F
7.4. Germany Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Market Outlook, 2016-2026F
7.5. France Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Market Outlook, 2016-2026F
7.6. Italy Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Market Outlook, 2016-2026F
7.5. Spain Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Market Outlook, 2016-2026F

8. Asia-Pacific Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Market Outlook, 2016-2026F

9. China Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Market Outlook, 2016-2026F

10. India Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Market Outlook, 2016-2026F

11. Japan Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Market Outlook, 2016-2026F

12. Australia Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Market Outlook, 2016-2026F

13. South Korea Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Market Outlook, 2016-2026F

14. Middle East and Africa Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Market Outlook, 2016-2026F

15. UAE Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Market Outlook, 2016-2026F

16. Saudi Arabia Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Market Outlook, 2016-2026F

17. Global Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Dynamics

18. Global Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Regulations, Product Standards

19. Global Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Value Chain Analysis

20. Global Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Intellectual Property Rights Analysis

21. Global Artificial Intelligence (AI) Enabled Drug Discovery and Clinical Trials Hotspots & Opportunities

22. Competition Outlook

For more information about this report visit https://www.researchandmarkets.com/r/wt0lv9


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Clarivate Declares Dividend on Mandatory Convertible Preferred Shares

Published

on

clarivate-declares-dividend-on-mandatory-convertible-preferred-shares

LONDON, May 1, 2024 /PRNewswire/ — Clarivate Plc (NYSE: CLVT; CLVT PR A) (“Clarivate”), a leading global provider of transformative intelligence, today announced that its board of directors declared a quarterly dividend of $1.3125 per share on its 5.25% Series A Mandatory Convertible Preferred Shares (the “Preferred Shares”), payable in cash on June 3, 2024 to shareholders of record at the close of business on May 15, 2024.

On the mandatory conversion date, which is scheduled to occur on June 3, 2024, each Preferred Share will automatically and mandatorily convert into a number of ordinary shares of Clarivate (and cash in lieu of any fractional ordinary shares) based on the average volume weighted average price (“VWAP”) of Clarivate’s ordinary shares over a 30-trading day period that begins on, and includes, April 18, 2024 and is scheduled to end on, and include, May 30, 2024 (the “valuation period”). If such VWAP is (i) greater than $31.20, then the mandatory conversion rate will be 3.2052 ordinary shares of Clarivate per Preferred Share, (ii) less than or equal to $31.20 but equal to or greater than $26.00, then the mandatory conversion rate will be a number of ordinary shares of Clarivate per Preferred Share equal to $100.00 divided by such VWAP and (iii) less than $26.00, then the mandatory conversion rate will be 3.8462 ordinary shares of Clarivate per Preferred Share. The mandatory conversion rate will be announced following the end of the valuation period. The above description of the terms of the Preferred Shares is not complete and is subject to, and qualified in its entirety by reference to, the “Statement of Rights” for the Preferred Shares, which is filed as Exhibit 3.2 to Clarivate’s annual report on Form 10-K for the fiscal year ended December 31, 2023.
Cautionary Note Regarding Forward-Looking Statements
This communication contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements, which express management’s current views concerning future business, events, trends, contingencies, financial performance, or financial condition, appear at various places in this communication and may use words like “aim,” “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “goal,” “intend,” “likely,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “see,” “seek,” “should,” “strategy,” “strive,” “target,” “will,” and “would” and similar expressions, and variations or negatives of these words. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management’s current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. These forward-looking statements involve a number of risks and uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include those factors discussed under the caption “Risk Factors” in our annual report on Form 10-K, along with our other filings with the U.S. Securities and Exchange Commission (“SEC”). However, those factors should not be considered to be a complete statement of all potential risks and uncertainties. Additional risks and uncertainties not known to us or that we currently deem immaterial may also adversely affect our business operations. Forward-looking statements are based only on information currently available to our management and speak only as of the date of this communication. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, except as otherwise required by securities and other applicable laws. Please consult our public filings with the SEC or on our website at www.clarivate.com.
About Clarivate
Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com.
Logo – https://mma.prnewswire.com/media/1159266/Clarivate_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/clarivate-declares-dividend-on-mandatory-convertible-preferred-shares-302133633.html

Continue Reading

Artificial Intelligence

CGTN: 3rd CMG Forum in Beijing discusses AI development

Published

on

cgtn:-3rd-cmg-forum-in-beijing-discusses-ai-development

BEIJING, May 1, 2024 /PRNewswire/ — Focusing on the development of AI, the third CMG Forum was held on Monday in Beijing.

Li Shulei, a member of the Political Bureau of the Communist Party of China (CPC) Central Committee and the head of the Publicity Department of the CPC Central Committee, attended the opening of the event and delivered a speech.
Guests at the forum stressed the role of media in promoting the innovative application of AI as well as its governance.
Efforts should also be made to boost the development of AI in creating positive, healthy, diverse and high-quality content, so that AI can become a force for good and benefit mankind, they agreed.
They also called on media to accelerate intelligent transformation and help bridge international exchanges and cooperation on the governance of AI to facilitate its healthy, orderly and safe development.
Hosted by China Media Group (CMG), the forum attracted more than 200 participants from international organizations, media, think tanks and multinational companies.
“Innovation and breakthroughs in science and technology not only guide the development and progress of human civilization, but also bring uncertainty to the changing world,” said Shen Haixiong, vice minister of the Publicity Department of the CPC Central Committee and president of CMG. He called for efforts to jointly create valuable and responsible artificial intelligence.
AI technology is affecting every aspect of our lives. Thomas Bach, president of the International Olympic Committee (IOC), stated in a video speech that CMG has always been a partner of the IOC, bringing the charm of the Olympic Games to hundreds of millions of Chinese viewers. He said the IOC invites CMG to work together for the creation of a future with the application of AI in Olympic sports.
“From ancient inventions such as silk, printing and the compass to modern technological advances such as robotics, telecommunications and green technology, China has always been committed to innovation and creation,” said Daren Tang, director general of the World Intellectual Property Organization (WIPO). He said WIPO pays close attention to ensuring a balance between the opportunities and risks of artificial intelligence and is committed to strengthening cooperation to ensure that artificial intelligence is properly used.
https://news.cgtn.com/news/2024-04-30/3rd-CMG-Forum-in-Beijing-discusses-AI-development-1tdDcXvCexG/p.html

View original content:https://www.prnewswire.co.uk/news-releases/cgtn-3rd-cmg-forum-in-beijing-discusses-ai-development-302133410.html

Continue Reading

Artificial Intelligence

Trianz Appoints Sridhar Kannan as Practice Leader – Digital, Elevating its Leadership in the Global Digital Transformation Space

Published

on

trianz-appoints-sridhar-kannan-as-practice-leader-–-digital,-elevating-its-leadership-in-the-global-digital-transformation-space

SANTA CLARA, Calif., May 1, 2024 /PRNewswire/ — Digital transformation technology & services company Trianz is pleased to announce the appointment of Sridhar Kannan as Practice Leader – Digital. With over 25 years of extensive experience in technology and business leadership, Sridhar joins Trianz to lead the expansion of Trianz’s Digital Practice, forging strategic alliances and expanding the business footprint.

Sridhar’s appointment comes at a transformative phase for Trianz as it solidifies its commitment to redefining the digital landscape with an “IP Led” model. This strategic shift is powered by Trianz’s cutting-edge hyper-automated platforms, Concierto.Cloud, Extrica.AI, and Pulse, driving industry-leading transformations in cloud, data and analytics, AI, and the digital workplace. Sridhar’s visionary leadership in technology-led business transformations across diverse sectors will be instrumental in leveraging IP-led models and innovative methodologies to position Trianz at the forefront of digital transformation.
“We are thrilled to welcome Sridhar Kannan to the Trianz family,” said Seshi Vanguru, Chief Revenue Officer at Trianz. “His appointment marks a significant stride in Trianz’s journey toward innovation and excellence. Sridhar’s wealth of experience and exceptional leadership skills will elevate our Digital Practice to new heights, reaffirming our commitment to delivering exceptional value to our clients.”
Sridhar is recognized as a client-focused technology and business transformation executive with a remarkable track record of helping Banking and Financial Services organizations in business transformation and product innovation using applications, cloud, data, and digital solutions. His extensive prior experience at industry giants such as Wipro, Cognizant, and Infosys include successfully leading Fortune 10 global client relationships and implementing transformative solutions across Banking, Financial Services, and Healthcare industries. Sridhar is highly regarded for his ability to lead global cross-functional teams, foster collaboration, and achieve aggressive business goals while consistently delivering high levels of client satisfaction.
“I am deeply honored to join Trianz and contribute to its mission of shaping the future through digital transformation,” said Sridhar. “Together, we will push the boundaries of what’s possible and drive meaningful impact for our clients in this rapidly evolving digital landscape.”
Based out of Minnesota, US, Sridhar has steered numerous clients towards success through the strategic application of Digital, Cloud, Product Engineering, Data, AI, and Application services, making him a seasoned strategist in today’s dynamic digital landscape. His appointment marks a significant milestone in Trianz’s journey to nurturing talent and delivering world-class solutions.
About Trianz
Trianz is a leading-edge technology platforms and services company that accelerates digital transformations at Fortune 100 and emerging companies worldwide in data & analytics, digital experiences, cloud infrastructure, and security. Our “IP Led Transformations” approach, informed by insights from a recent global study spanning 20+ industries and 5000+ companies, addresses challenges posed by the rapid pace of AI-driven transformation, digital talent scarcity, and economic uncertainty. Our IP and platforms, including Concierto, Extrica, and Pulse, revolutionize cloud adoption, data analytics, and AI insights, empowering organizations to navigate the complexities of digital transformation seamlessly.
Founded in California and with an organization of over 2,000 associates across the United States and India, Trianz is a Premier Partner of AWS, consistently rated #1 by clients for value delivery over the past five years. Trianz has been ranked as one of the best Consulting Firms by Forbes and has been certified as a Great Place to Work for three years in a row. To learn more about Trianz, email [email protected] or visit www.trianz.com.
Watch Trianz CEO Sri Manchala’s insightful interview with Bloomberg on Partner | Crossing The Digital Faultline & Leading Towards Transformative Success – YouTube and delve deeper into his book Crossing the Digital Faultline at Crossing the Digital Faultline | Trianz.
Trianz Media Team : [email protected]+1-408-387-5800
Logo: https://mma.prnewswire.com/media/626944/1199800/Trianz_Logo.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/trianz-appoints-sridhar-kannan-as-practice-leader–digital-elevating-its-leadership-in-the-global-digital-transformation-space-302132835.html

Continue Reading

Trending